APP and Alzheimer disease: Arecent study showed that treating mouse models of AD with oral dosesof a QC inhibitor resulted in reduced pyroglutamate Abeta burden,diminished plaque formation, and improved cognition.18 Other work has shown that treating mice with anti-Abeta-pE3monoclonal antibodies resulted in the attenuation of behavioral deficitsand clearance of Abeta in preclinical mouse models.38 Taking all of these promising data into account, thereis merit in developing imaging technology to help to assess theseobservations noninvasively.